GB201506786D0 - Therapeutic use - Google Patents

Therapeutic use

Info

Publication number
GB201506786D0
GB201506786D0 GBGB1506786.1A GB201506786A GB201506786D0 GB 201506786 D0 GB201506786 D0 GB 201506786D0 GB 201506786 A GB201506786 A GB 201506786A GB 201506786 D0 GB201506786 D0 GB 201506786D0
Authority
GB
United Kingdom
Prior art keywords
therapeutic use
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1506786.1A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Biopharma SRL
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Priority to GBGB1506786.1A priority Critical patent/GB201506786D0/en
Publication of GB201506786D0 publication Critical patent/GB201506786D0/en
Priority to JP2017554426A priority patent/JP6721606B2/ja
Priority to PCT/EP2016/058810 priority patent/WO2016170014A1/en
Priority to PL16719356T priority patent/PL3285772T3/pl
Priority to HRP20192273TT priority patent/HRP20192273T1/hr
Priority to HUE16719356A priority patent/HUE047162T2/hu
Priority to LTEP16719356.4T priority patent/LT3285772T/lt
Priority to EA201792318A priority patent/EA032432B1/ru
Priority to MYPI2017703917A priority patent/MY192972A/en
Priority to CA2981631A priority patent/CA2981631C/en
Priority to DK16719356.4T priority patent/DK3285772T3/da
Priority to AU2016251236A priority patent/AU2016251236B2/en
Priority to MX2017013148A priority patent/MX2017013148A/es
Priority to SI201630565T priority patent/SI3285772T1/sl
Priority to PT167193564T priority patent/PT3285772T/pt
Priority to ES16719356T priority patent/ES2763335T3/es
Priority to CN201680022982.1A priority patent/CN107530344B/zh
Priority to BR112017020591A priority patent/BR112017020591B8/pt
Priority to KR1020177031275A priority patent/KR102627370B1/ko
Priority to US15/565,866 priority patent/US10493074B2/en
Priority to SG11201707789YA priority patent/SG11201707789YA/en
Priority to EP16719356.4A priority patent/EP3285772B1/en
Priority to ARP160101079A priority patent/AR105552A1/es
Priority to IL254766A priority patent/IL254766B/en
Priority to CONC2017/0010573A priority patent/CO2017010573A2/es
Priority to CL2017002669A priority patent/CL2017002669A1/es
Priority to CY20191101354T priority patent/CY1122572T1/el
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
GBGB1506786.1A 2015-04-21 2015-04-21 Therapeutic use Ceased GB201506786D0 (en)

Priority Applications (27)

Application Number Priority Date Filing Date Title
GBGB1506786.1A GB201506786D0 (en) 2015-04-21 2015-04-21 Therapeutic use
ARP160101079A AR105552A1 (es) 2015-04-21 2016-04-20 Un análogo específico de trifluoroetilquinolina para usar en el tratamiento de síndrome de sjögren
MX2017013148A MX2017013148A (es) 2015-04-21 2016-04-20 Analogo de trifluoroetil quinolina especifico para usarse en el tratamiento del sindrome de sjögren.
PT167193564T PT3285772T (pt) 2015-04-21 2016-04-20 Nálogo de trifluoroetil quinolina específico para utilização no tratamento da síndrome de sjögren
PL16719356T PL3285772T3 (pl) 2015-04-21 2016-04-20 Konkretna pochodna trifluoroetylochinoliny do zastosowania w leczeniu zespołu Sjögrena
HRP20192273TT HRP20192273T1 (hr) 2015-04-21 2016-04-20 Specifični trifluoroetil analozi kinolina za upotrebu u liječenju sjögrenovog sindroma
HUE16719356A HUE047162T2 (hu) 2015-04-21 2016-04-20 Specifikus trifluoretil-kinolin analóg Sjögren-szindróma kezelésében történõ alkalmazásra
LTEP16719356.4T LT3285772T (lt) 2015-04-21 2016-04-20 Specifinis trifluoroetilkinolino analogas, naudojamas sjögreno sindromo gydymui
EA201792318A EA032432B1 (ru) 2015-04-21 2016-04-20 Специфический аналог трифторэтилхинолина для применения при лечении синдрома шегрена
MYPI2017703917A MY192972A (en) 2015-04-21 2016-04-20 A specific trifluoroethyl quinoline analogue for use in the treatment of sjogren's syndrome
CA2981631A CA2981631C (en) 2015-04-21 2016-04-20 A specific trifluoroethyl quinoline analogue for use in the treatment of sjogren's syndrome
DK16719356.4T DK3285772T3 (da) 2015-04-21 2016-04-20 En specifik trifluorethylquinolinanalog til anvendelse ved behandlingen af sjögrens syndrom
AU2016251236A AU2016251236B2 (en) 2015-04-21 2016-04-20 A specific trifluoroethyl quinoline analogue for use in the treatment of Sjögren's syndrome
JP2017554426A JP6721606B2 (ja) 2015-04-21 2016-04-20 シェーグレン症候群の治療にける使用のための特定のトリフルオロエチルキノリン類似体
SI201630565T SI3285772T1 (sl) 2015-04-21 2016-04-20 Specifični analog trifluoroetil kinolina za uporabo pri zdravljenju Sjoegrenovega sindroma
PCT/EP2016/058810 WO2016170014A1 (en) 2015-04-21 2016-04-20 A specific trifluoroethyl quinoline analogue for use in the treatment of sjögren's syndrome
ES16719356T ES2763335T3 (es) 2015-04-21 2016-04-20 Un análogo de trifluoroetil quinoleína específico para uso en el tratamiento del síndrome de Sjögren
CN201680022982.1A CN107530344B (zh) 2015-04-21 2016-04-20 用于治疗干燥综合征的特定三氟乙基喹啉类似物
BR112017020591A BR112017020591B8 (pt) 2015-04-21 2016-04-20 Uso de n-{(r)-1-[8-cloro-2-(1-oxipiridin-3-il)quinolin-3-il]-2,2,2-trifluoroetil}pirido[3,2-d]pirimidin-4-ilamina
KR1020177031275A KR102627370B1 (ko) 2015-04-21 2016-04-20 쇼그렌 증후군의 치료에 사용하기 위한 특정 트리플루오로에틸 퀴놀린 유사체
US15/565,866 US10493074B2 (en) 2015-04-21 2016-04-20 Specific trifluoroethyl quinoline analogue for use in the treatment of Sjögren's syndrome
SG11201707789YA SG11201707789YA (en) 2015-04-21 2016-04-20 A specific trifluoroethyl quinoline analogue for use in the treatment of sjögren's syndrome
EP16719356.4A EP3285772B1 (en) 2015-04-21 2016-04-20 A specific trifluoroethyl quinoline analogue for use in the treatment of sjögren's syndrome
IL254766A IL254766B (en) 2015-04-21 2017-09-28 A certain analog of trifluoroethyl quinoline for use in the treatment of Sjögren's syndrome
CONC2017/0010573A CO2017010573A2 (es) 2015-04-21 2017-10-17 Un análogo de trifluoroetil quinolina específico para uso en el tratamiento del síndrome de sjögren
CL2017002669A CL2017002669A1 (es) 2015-04-21 2017-10-20 Un análogo de quinolina trifluoroetil específico para uso en el tratamiento del síndrome de sjögren
CY20191101354T CY1122572T1 (el) 2015-04-21 2019-12-23 Συγκεκριμενο αναλογο τριφθοροαιθυλο κινολινης για χρηση στη θεραπεια του συνδρομου sjögren

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1506786.1A GB201506786D0 (en) 2015-04-21 2015-04-21 Therapeutic use

Publications (1)

Publication Number Publication Date
GB201506786D0 true GB201506786D0 (en) 2015-06-03

Family

ID=53298950

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1506786.1A Ceased GB201506786D0 (en) 2015-04-21 2015-04-21 Therapeutic use

Country Status (27)

Country Link
US (1) US10493074B2 (cg-RX-API-DMAC7.html)
EP (1) EP3285772B1 (cg-RX-API-DMAC7.html)
JP (1) JP6721606B2 (cg-RX-API-DMAC7.html)
KR (1) KR102627370B1 (cg-RX-API-DMAC7.html)
CN (1) CN107530344B (cg-RX-API-DMAC7.html)
AR (1) AR105552A1 (cg-RX-API-DMAC7.html)
AU (1) AU2016251236B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017020591B8 (cg-RX-API-DMAC7.html)
CA (1) CA2981631C (cg-RX-API-DMAC7.html)
CL (1) CL2017002669A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017010573A2 (cg-RX-API-DMAC7.html)
CY (1) CY1122572T1 (cg-RX-API-DMAC7.html)
DK (1) DK3285772T3 (cg-RX-API-DMAC7.html)
EA (1) EA032432B1 (cg-RX-API-DMAC7.html)
ES (1) ES2763335T3 (cg-RX-API-DMAC7.html)
GB (1) GB201506786D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20192273T1 (cg-RX-API-DMAC7.html)
HU (1) HUE047162T2 (cg-RX-API-DMAC7.html)
IL (1) IL254766B (cg-RX-API-DMAC7.html)
LT (1) LT3285772T (cg-RX-API-DMAC7.html)
MX (1) MX2017013148A (cg-RX-API-DMAC7.html)
MY (1) MY192972A (cg-RX-API-DMAC7.html)
PL (1) PL3285772T3 (cg-RX-API-DMAC7.html)
PT (1) PT3285772T (cg-RX-API-DMAC7.html)
SG (1) SG11201707789YA (cg-RX-API-DMAC7.html)
SI (1) SI3285772T1 (cg-RX-API-DMAC7.html)
WO (1) WO2016170014A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
GB201708856D0 (en) 2017-06-02 2017-07-19 Ucb Biopharma Sprl Seletalisib crystalline forms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2612862T (lt) * 2004-05-13 2017-01-25 Icos Corporation Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai
HRP20160350T1 (hr) * 2007-03-23 2016-05-06 Amgen Inc. Heterociklički spojevi i njihove uporabe
LT2496567T (lt) * 2009-11-05 2017-11-27 Rhizen Pharmaceuticals S.A. Nauji benzopirano kinazės moduliatoriai
UA112517C2 (uk) * 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
AR082799A1 (es) * 2010-09-08 2013-01-09 Ucb Pharma Sa Derivados de quinolina y quinoxalina como inhibidores de quinasa
ES2667173T3 (es) * 2013-06-14 2018-05-09 Gilead Calistoga Llc Inhibidores de fosfatidilinositol 3-quinasa

Also Published As

Publication number Publication date
IL254766B (en) 2020-05-31
AU2016251236A1 (en) 2017-11-09
EA032432B1 (ru) 2019-05-31
CY1122572T1 (el) 2021-01-27
CA2981631C (en) 2023-02-21
ES2763335T3 (es) 2020-05-28
SG11201707789YA (en) 2017-11-29
JP6721606B2 (ja) 2020-07-15
EA201792318A1 (ru) 2018-05-31
HRP20192273T1 (hr) 2020-03-06
US10493074B2 (en) 2019-12-03
EP3285772B1 (en) 2019-10-02
KR102627370B1 (ko) 2024-01-18
PL3285772T3 (pl) 2020-05-18
BR112017020591B8 (pt) 2023-05-16
LT3285772T (lt) 2020-01-10
CO2017010573A2 (es) 2018-03-09
KR20170140245A (ko) 2017-12-20
SI3285772T1 (sl) 2020-02-28
HUE047162T2 (hu) 2020-04-28
EP3285772A1 (en) 2018-02-28
AU2016251236B2 (en) 2018-06-14
IL254766A0 (en) 2017-12-31
CN107530344B (zh) 2020-03-17
MX2017013148A (es) 2018-02-21
CL2017002669A1 (es) 2018-05-11
WO2016170014A1 (en) 2016-10-27
BR112017020591A2 (pt) 2018-07-03
PT3285772T (pt) 2020-01-14
US20180092921A1 (en) 2018-04-05
CN107530344A (zh) 2018-01-02
MY192972A (en) 2022-09-20
BR112017020591B1 (pt) 2023-02-07
JP2018513862A (ja) 2018-05-31
CA2981631A1 (en) 2016-10-27
AR105552A1 (es) 2017-10-18
DK3285772T3 (da) 2020-01-13

Similar Documents

Publication Publication Date Title
SG10201912416QA (en) Therapeutic agents
HUE051354T2 (hu) Terapeutikum
GB201509893D0 (en) Therapeutic agents
GB201516442D0 (en) Combination therapy
GB201517263D0 (en) Therapeutic agents
IL257976A (en) Combined treatment
GB201410816D0 (en) Therapeutic agents
GB201410216D0 (en) Therapeutic
GB201410815D0 (en) Therapeutic agents
ZA201804155B (en) Combination therapy
GB201509885D0 (en) Therapeutic agents
GB201502412D0 (en) Therapeutic use
GB201608797D0 (en) Therapeutic use
GB201509888D0 (en) Therapeutic agents
GB201513299D0 (en) Therapeutic agents
GB201510637D0 (en) Therapeutic
GB201521085D0 (en) Use
GB201521767D0 (en) Therapeutic agents
GB201517264D0 (en) Therapeutic agents
GB201410334D0 (en) Therapeutic
GB201516494D0 (en) New therapeutic use
GB201502415D0 (en) New therapeutic use
GB201521755D0 (en) Therapeutic agents
GB201521683D0 (en) Therapeutic agents
GB201520808D0 (en) Therapeutic agents

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)